Management and mechanism of calciphylaxis in a patient treated with the FGFR inhibitor pemigatinib-a case report

被引:0
|
作者
Chandana, Sreenivasa R. [1 ,2 ]
Frisch, Austin [3 ]
Mendoza, Sergio [3 ]
Sinniah, Ranu S. [3 ]
Crysler, Oxana [4 ]
Banga, Ramandeep [5 ]
Perkins, Diane E. [6 ]
机构
[1] Canc & Hematol Ctr, 145 Michigan St,NE,Suite 3100, Grand Rapids, MI 49503 USA
[2] Michigan State Univ, Coll Human Med, Dept Med, E Lansing, MI 48824 USA
[3] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA
[4] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA
[5] Renal Associates West Michigan, Grand Rapids, MI USA
[6] Spectrum Hlth, Dept Pathol, Grand Rapids, MI USA
关键词
Calciphylaxis; pemigatinib; small molecule inhibitor; case report; CHOLANGIOCARCINOMA;
D O I
10.21037/jgo-23-139
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Small molecule fibroblast growth factor receptor (FGFR) inhibitors, such as pemigatinib, have been developed for the treatment of cholangiocarcinoma (CCA) with rearrangements or fusions in the FGFR2. FGFR inhibitors (FGFRis) have dermatologic side effects such as dry skin or nail bed damage. However, in very rare instances, a life -threatening vascular calcification disease known as calciphylaxis has been linked to these therapies. Case Description: We report a patient with metastatic CCA, who developed calciphylaxis following the start of their pemigatinib treatment. Calciphylaxis is associated with skin lesions and affects the dermal microvasculature in addition to the vascular calcification. This case focuses on the management strategy used for this rare adverse event (AE) as well as the pathology and complicated mechanism of calciphylaxis. We highlight the unclear pathophysiology behind this disease by identifying key players in the signaling and molecular pathways in the microenvironment that are needed to trigger this pathology. Conclusions: Calciphylaxis is normally associated with advanced renal failure in the setting of high phosphate and calcium. However, the patient we present here did not have advanced renal failure or high calcium levels and calcium dysregulation. As FGFRi use becomes more widespread, the more important it becomes to identify and have a treatment strategy for this rare AE.
引用
收藏
页码:478 / 484
页数:7
相关论文
共 50 条
  • [21] Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report
    Claudia Colomba
    Raffaella Rubino
    Lucia Siracusa
    Francesco Lalicata
    Marcello Trizzino
    Lucina Titone
    Manlio Tolomeo
    BMC Research Notes, 5 (1)
  • [22] SEVERE CARDIOTOXICITY IN A PATIENT WITH RENAL CELL CARCINOMA TREATED WITH MTOR INHIBITOR: A CASE REPORT
    Shioyama, W.
    Mukai, M.
    Tone, E.
    Harada, H.
    Awata, N.
    Hori, M.
    Arai, Y.
    Nishimura, K.
    Yamazaki, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 154 - 154
  • [23] Calciphylaxis in a Patient With Non-Hodgkin Lymphoma: Case Report and Literature Review
    Morand, Meggie
    Chababi-Atallah, Myrna
    Jean, Sara-Elizabeth
    Fernandes, Carolina
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2018, 22 (05) : 524 - 526
  • [24] Calciphylaxis during the course of psoriatic arthritis patient. Is it coincidence? A case report
    Khalayli, Naram
    Hodifa, Yara
    Hodaifa, Amr
    Alsamarrai, Omar
    Kudsi, Maysoun
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (10): : 5263 - 5266
  • [25] Persistent response to combination treatment of pemigatinib and chemotherapy in a patient with advanced gastric cancer:A case report
    Jing Wu
    Yuehong Cui
    Shan Yu
    Malignancy Spectrum, 2024, 1 (03) : 217 - 222
  • [26] Surgical Management of Calciphylaxis Associated with Primary Hyperparathyroidism: A Case Report and Review of the Literature
    Bishop, Jennifer
    Brown, Eric
    Podesta, Augusto
    Troy, Cathrine
    Dong, Xiang
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2010, 2010
  • [27] Synergy of sodium thiosulphate treatment and expanded hemodialysis in the management of calciphylaxis? A case report
    Valga, Francisco
    Monzon, Tania
    Rincon, Marian
    Vega-Diaz, Nicanor
    Carlos de la Flor, Jose
    Aladro Escribano, Sara
    Santana-Quintana, Adonay
    Santana-Estupinan, Raquel
    Carlos Rodriguez-Perez, Jose
    NEFROLOGIA, 2022, 42 (03): : 354 - 356
  • [29] Acute coronary syndrome in a patient with gastric cancer treated by immune checkpoint inhibitor: A case report
    Bin Guan
    Lingyun Zhang
    Shan Yu
    Malignancy Spectrum, 2024, 1 (02) : 136 - 140